Status:
TERMINATED
Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease
Lead Sponsor:
San Filippo Neri General Hospital
Collaborating Sponsors:
Associazione Nazionale Medici Cardiologi Ospedalieri
Conditions:
Acute Coronary Syndrome
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute...
Eligibility Criteria
Inclusion
- non-ST-segment elevation acute myocardial infarction.
- coronary angiography within 48 hours from admission.
- angiographic evidence of severe and diffuse coronary artery disease,not amenable to conventional direct revascularisation techniques by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).
Exclusion
- ST-segment elevation acute myocardial infarction,
- clinical history of heart failure
- left ventricular ejection fraction \<35%,
- any form of severe valvular dysfunction,
- previous implantation or indication to implant a cardioverter-defibrillator during the index admission,
- any increase in liver enzymes,
- history of any liver or muscle disease,
- renal failure with serum creatinine \>2.5 mg/dL (221 mmol/L),
- need for continued use of intravenous medications to relieve anginal symptoms,
- presence of any major comorbidity with life expectancy \<24 months.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT01187992
Start Date
September 1 2003
End Date
April 1 2007
Last Update
August 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Filippo Neri General Hospital
Rome, Italy, Italy, I-00135